Acquisition by Akinsanya Karen of 14411 shares of Nautilus Biotechnology subject to Rule 16b-3
NAUT Stock | USD 1.95 0.09 4.41% |
Slightly above 58% of Nautilus Biotechnology's investor base is looking to short. The analysis of the overall investor sentiment regarding Nautilus Biotechnology suggests that many traders are alarmed. Nautilus Biotechnology's investing sentiment can be driven by a variety of factors including economic data, Nautilus Biotechnology's earnings reports, geopolitical events, and overall market trends.
Nautilus |
Filed transaction by Nautilus Biotechnology Director . Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Cash Flow Correlation
Nautilus Biotechnology's cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Nautilus Biotechnology's relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Nautilus Biotechnology Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Nautilus Biotechnology can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Nautilus Biotechnology Fundamental Analysis
We analyze Nautilus Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nautilus Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nautilus Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Asset
Total Asset Comparative Analysis
Nautilus Biotechnology is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Nautilus Biotechnology Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Nautilus Biotechnology stock to make a market-neutral strategy. Peer analysis of Nautilus Biotechnology could also be used in its relative valuation, which is a method of valuing Nautilus Biotechnology by comparing valuation metrics with similar companies.
Peers
Nautilus Biotechnology Related Equities
BEAM | Beam Therapeutics | 3.58 | ||||
KYMR | Kymera Therapeutics | 2.21 | ||||
ANEB | Anebulo Pharmaceuticals | 0.72 | ||||
MNOV | MediciNova | 0.48 | ||||
RVMD | Revolution Medicines | 0.18 | ||||
CSBR | Champions Oncology | 1.26 | ||||
PMVP | Pmv Pharmaceuticals | 1.27 | ||||
MOLN | Molecular Partners | 1.47 | ||||
CRBU | Caribou Biosciences | 1.55 | ||||
CCCC | C4 Therapeutics | 1.60 | ||||
RZLT | Rezolute | 2.18 | ||||
IPSC | Century Therapeutics | 2.40 | ||||
BCAB | Bioatla | 6.90 | ||||
HCWB | HCW Biologics | 7.69 | ||||
FHTX | Foghorn Therapeutics | 8.30 | ||||
DTIL | Precision BioSciences | 11.11 |
Additional Tools for Nautilus Stock Analysis
When running Nautilus Biotechnology's price analysis, check to measure Nautilus Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nautilus Biotechnology is operating at the current time. Most of Nautilus Biotechnology's value examination focuses on studying past and present price action to predict the probability of Nautilus Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nautilus Biotechnology's price. Additionally, you may evaluate how the addition of Nautilus Biotechnology to your portfolios can decrease your overall portfolio volatility.